Stoke Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2018 | — | $105.1M | $105.4M |
| FY2019 | — | $224.4M | $222.5M |
| FY2020 | — | $286.1M | $287.3M |
| FY2021 | — | $217.8M | $144.9M |
| FY2022 | — | $184.8M | $113.6M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2018 | — | $105.1M | $105.4M |
| FY2019 | — | $224.4M | $222.5M |
| FY2020 | — | $286.1M | $287.3M |
| FY2021 | — | $217.8M | $144.9M |
| FY2022 | — | $184.8M | $113.6M |